Drugs / LY3985863
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07030127 | Aug 2025 → Feb 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3985863 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07030127 ↗ |
| Route | Subcutaneous | “The study drug will be administered subcutaneously (SC) (under the skin).” NCT07030127 ↗ |